Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

Pyxis Oncology (NASDAQ: PYXS) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $16.15 million which beat the analyst consensus estimate of $13.81 million by 16.89 percent.